Learning Zone

Coming soon!

Medical education and communication on key topics in the area of immunology. Content in this section will be sponsored by the pharmaceutical industry.

Don’t forget to register with touchIMMUNOLOGY to be the first to hear about new activity launches.

Examples of our work

In the meantime, browse some of the free-to-access activities on our sister sites:

Renal Cancer

touchEXPERT BRIEFING

The Role of High-Dose IL-2 in mRCC today

Dr Scott S Tykodi and Dr Brendan Curti Watch Time: 20 mins

High-dose interleukin-2 therapy is one of the few treatments for adults with metastatic renal cell cancer (mRCC) that can produce complete responses that are often durable for decades without further therapy.1-3 We interviewed leading experts about the current status of high-dose interleukin-2 therapy,1 when and how it should be considered,4 recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 the findings from a recent analysis of the PROCLAIMSM registry into the efficacy of high-dose interleukin-2 therapy in favorable-risk mRCC patients,2,7 and the impact of these developments on the overall treatment paradigm.

Multiple Sclerosis

touchFEATURE

Management of MS: Let’s Get Personal

Gavin Giovannoni, Ester Moral, Klaus Schmierer, Laura Airas, Hanne F Harbo, Paul Matthews Watch Time: 62 mins

Peer-to-peer, clinically relevant, evidence-based medical educational programs – such as this acadeMe Medical Education program – filmed at the 2019 acadeMe MS Annual Conference – Management of MS: Let’s Get Personal- are critically important in our efforts to address the unmet medical education needs of the healthcare professionals responsible for the care of patients with MS. The aim of this educational resource is to enable healthcare professionals to make better-informed diagnostic and treatment decisions, ultimately resulting in improved MS patient outcomes.

Content in this section is sponsored by the pharmaceutical industry and is developed by Touch Medical Communications (TMC) for touchIMMUNOLOGY.

TMC’s mission is to provide HCPs with key education and communication through our unique Touch platform which combines clinical expertise with unparalleled society partnerships, long-term expert relationships and the Touch journal heritage, ultimately leading to fast implementation of positive clinical practice changes and improved patient outcomes. TMC’s "learner first" approach means that programming is delivered in multiple formats and can be accessed via multiple platforms, including mobile, allowing today’s on-the-go healthcare professionals to learn in the way that best suits them.